Point72 (DIFC)’s Inhibikase Therapeutics IKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-1,980
Closed -$4.34K 1826
2025
Q1
$4.34K Buy
+1,980
New +$4.97K ﹤0.01% 1532

Other funds holding IKT

Point72 (DIFC)'s IKT Position: Q2 2025 in Review

Point72 (DIFC) sold out of Inhibikase Therapeutics (IKT) in Q2 2025, closing a stake of 1,980 shares — an estimated $4.34K sold.

Point72 (DIFC) first reported a position in IKT in Q1 2025 and held it in 1 quarter. The position peaked at $4.34K in Q1 2025. 48 funds tracked by Wall St. Rank hold IKT as of Q2 2025.

  • Point72 (DIFC) reported no remaining Inhibikase Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 1,980 Inhibikase Therapeutics shares in Q2 2025, an estimated $4.34K.
  • Point72 (DIFC) first reported a position in Inhibikase Therapeutics in Q1 2025 and held it in 1 quarter.
  • Point72 (DIFC)'s Inhibikase Therapeutics position peaked at $4.34K in Q1 2025.
  • 48 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2025.

Based on Point72 (DIFC)'s 13F filing for Q2 2025, filed 14 Aug 2025.